Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial.

PLoS One · 2025 · PMC12449008 · PMID 40971945

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Improvements in sleep maintenance, duration and quality Numerically greater improvements in WASO and WASOTO6 were noted on Night 1, but these values did not reach statistical significance.

also in 111,027 other papers

highly significantno p-value reported

In combination with the highly significant first night clinical benefits presented above, it is reasonable to assume that intermittent usage, when needed, of tasimelteon is effective in treating sleep-onset insomnia.

also in 132,142 other papers

did not achieve significanceno p-value reported

Moreover, although other sleep measures did not achieve significance, they all showed numerical improvements over placebo.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.